Effect of Ticlopidine and Aspirin on Platelet Ionized Calcium in Ischemic Stroke
To the Editor Ticlopidine, 5-(o-chlorobenzyl)-4,5,6,7,-tetrahydrothieno[3,2-c] pyridine hydrochloride, a newer antiplatelet drug, has recently been shown to be better than aspirin in the secondary prevention of cerebral ischemia. 1 The exact mechanism by which ticlopidine exerts its antiplatelet effect is unknown. 2 Changes in platelet ionized calcium concentration ([Cai 2+ ]) are believed to be involved, 3 but this possibility has not been studied in stroke. Accordingly, we compared the effects of aspirin and ticlopidine on baseline and activated platelet [Caj 2+ ] in patients with ischemic stroke. Fifty-one ischemic stroke patients were studied; 22 had not taken antiplatelet drugs for at least 14 days before or after the onset of stroke (Group 1), 17 were on aspirin in a dosage of 325 mg daily for 4.2±2.1 (mean±SD) years (Group 2), and 12 were taking ticlopidine 500 mg twice daily for 2.5 ±1.9 years (Group 3). The groups were reasonably matched for age, major stroke risk factors (hypertension, diabetes, and smoking), and for concurrent other medications. Ischemic stroke was diagnosed based on the sudden onset of a focal neurological deficit lasting for more than 24 hours. Computed tomography (CT) scan excluded hemorrhage and tumor in all patients, and we observed no major differences on CT, echocardiography, and 24 -hour cardiac Holter among the stroke subgroups. Groups 1 and 2 were studied 2.9±2.1 and 3.0±1.8 days after the onset of stroke, respectively. In group 2, five patients had been taking aspirin as a primary preventative for vascular disease, five for pain/arthralgias, four following myocardial infarction, and three following previous ischemic stroke. Group 3 patients were all participants in the Canadian American Ticlopidine Study (CATS) in thromboembolic stroke 1 and had been on prophylactic treatment with ticlopidine following onset of stroke. Platelet [CV + ] was measured in aequorin-loaded, gel-filtered washed platelets as previously described. 4 - 5 Final concentrations of collagen (ChronoLog Corp., Havertown, Pa.) (2 and 4 /ig/ml), thrombin (Parke Davis) (0.5 and 1.0 unit/ml), and platelet activating factor (Calbiochem Corp., La Jolla, Calif.) (5 and 10 /iM) were the stimulating agents applied. Student's t test was used to test for differences in baseline and activated platelet [Cai 2+ ].
Compared with levels in untreated patients, platelet levels of baseline [Ca< 2+ ] decreased only in patients taking aspirin (Table 1) . Although collagen-and thrombin-induced increases in platelet [CV + ] w e r e inhibited in both the aspirin-and ticlopidine-treated patients, neither treatment inhibited platelet activating factorinduced responses. Compared with the aspirin-treated group, the ticlopidine-treated patients had a higher baseline [CV + ] and less inhibition of collagen-and platelet activating factor-induced responses. Taken together, our results suggest that while ticlopidine inhibits some measurements of platelet [Ca, 2+ ], the effects are less pronounced than with aspirin. Therefore, mechanisms other than platelet inhibition may need to be considered as contributing to the relatively greater clinical benefit of ticlopidine over aspirin.
Ticlopidine has favorable antithrombotic effects on leukocytes and erythrocytes, which interact with platelets during thrombus formation.
6 Therefore, the experimental observations that ticlopidine reduces platelet-dependent neutrophil activation 7 and increases the stability of erythrocyte membranes 8 may be clinically important. Recent observations that experimentally induced leukopenia is associated with reduced volume of infarction' raise the possibility that ticlopidine-induced leukopenia seen in some patients 1 may have therapeutic benefit. Ticlopidine reduces blood fibrinogen 10 and decreases blood viscosity, 8 which may also contribute to its beneficial effect. In conclusion, we have shown that ticlopidine, compared with aspirin, has a less pronounced effect in reducing platelet [Cai 2+ ]. Besides platelet inhibition, other mechanisms may contribute to the greater clinical efficacy of ticlopidine over aspirin. 
Effect of Emitted Power on Waveform Intensity in Transcranial Doppler
To the Editor:
The problem of obtaining usable signals in the transcranial Doppler examination of elderly females due to hyperostosis of the temporal bone has been evident since the early days of this technology. That this phenomenon is more pronounced in blacks and Orientals 1 is a particular source of frustration to those, such as Dr. James Halsey, working in areas with a high population of these stroke-prone groups. His attempt to quantify the role of increased acoustic emission in overcoming this problem 2 may cast more confusion than light on an area that is already unfamiliar to most clinical neurologists, unfortunately detracting from what is an important contribution to this subject.
The main fault is the failure to define adequately the units of ultrasonic emission being applied. This in turn calls into question the calibration of the transcranial Doppler system on which they are stated to be based and suggests that Halsey may have relied too heavily on the data provided by the manufacturers of the system used.
Our measurements on 14 such systems, which have been confirmed by other centers in Europe and the United States, show that ultrasonic emission is sometimes understated by as much as 70%.
In the title and summary of his article, 2 Halsey refers to emitted power, correctly expressed in milliwatts (mW), as he does elsewhere throughout the study. In describing the methodology, however, it becomes apparent that his values are really those of acoustic intensity, which are measured in milliwatts per square centimeter (mW/cm 2 ). To illustrate the magnitude of error that can occur by confusing these two very different units, it should be noted that, based on the data given for the transcranial Doppler system used, an emitted power of 800 mW would result in an intensity of between 4,000 and 6,000 mW/cm 2 (spatial peaktemporal average measured in water), depending upon the beam characteristics, which are not described. This makes it obvious that where Halsey uses the term "power" throughout his article, he really means "intensity." The confusion is compounded by using this term to describe a characteristic of the recorded waveform for which the term "amplitude" would have been more appropriate.
The units of intensity used by Halsey 2 are described as being in situ values, without definition of this term. One can only assume that this refers to the "estimated in situ intensities" defined by the Food and Drug Administration in its guide for measuring the acoustic output of ultrasound devices. 3 It is, however, only an estimate, based on the very low attenuation coefficients of amniotic fluid and urine, which are efficient vectors of ultrasound when used for fetal examination.
The situation in transcranial Doppler examination is very different, mainly because of the massive effects of the skull on the ultrasound beam, and can be more realistically evaluated by applying the unit of "estimated intracranial intensity" as I have defined it. 4 Since this is also a "worst case" value, formulated to minimize the risk of possible bioeffects of ultrasound on the tissues, it takes into account a 40% loss of acoustic energy due to the effects of the skull, based on in vitro measurements of an ultrasound beam passed through skull samples in a waterbath.
However, my small series of intraoperative measurements, made with miniaturized calibrated hydrophones during neurosurgery, *-5 show that even in a 9-year-old girl, only 6% of the emitted ultrasound was measured at the brain midline (94% attenuation) and that this value was as low as 2% (98% attenuation) for women in their forties.
The loss of acoustic energy is almost entirely due to reflection and not, as Halsey suggests, 2 "by absorption and scatter in the temporal bone." This is fortunate, since absorption of such high energy levels could give rise to problems of heating of the temporal periosteum. In our experience, this reflection of high ultrasonic power often causes an overloading of the transcranial Doppler system even at levels considerably lower than those applied by Halsey, resulting in disintegration of the Doppler signal. This can usually be eliminated by reducing the acoustic output, just as vision when driving in fog is improved by dimming the headlights to avoid the glaring reflections of the full beam. This self-defeating disadvantage of using higher acoustic intensities is not mentioned in Halsey's study.
For this reason, we take the approach of using less acoustic power in the examination of these problem patients, while seeking to increase the sensitivity of the transducer, for instance, by amplifying the backscattered rather than the emitted ultrasound. This approach is not only producing significantly improved Doppler signals, but reduces the risk of possible bioeffects due to unnecessarily high ultrasonic intensities. This consideration is of special importance now that transcTanial Doppler is increasingly used as a monitoring method over longer periods of time.
Our failure rate of less than 2%, with a patient population consisting almost entirely of females 50 years old or older, 5 is confirmed by other centers using probes of increased sensitivity. However, we have very few black patients in central Europe, and I am therefore particularly pleased that Dr. Halsey has agreed to collaborate with us in a study to evaluate very carefully our approach in this stroke-prone group of patients.
